Abstract
By exposing Igrov-1 human ovarian cancer cells to increasing concentrations of Ecteinascidin-743 (ET-743), either for a short or prolonged time, we obtained sublines resistant to ET-743 which overexpress Pgp. The most resistant clone (Igrov-1/25 ET) was evaluated for biological and pharmacological characterizations. The increased Pgp levels of Igrov-1/25 ET were not due to amplification of the mdr-1 gene but to increased mRNA levels. No increase in other multidrug resistance-related proteins such as MRP or LRP was observed in Igrov-1/25 ET. The IC50values of ET-743 against Igrov-1/25 ET was approximately 50 times higher than the parental cell line. Resistance was not reversed while maintaining the cell line in drug-free medium for at least 24 months. Igrov-1/25 ET was cross-resistant to Doxorubicin and VP16 while it was equally sensitive to L-PAM, MNNG, CPT and only marginally less sensitive to Cis-DDP and Oxaliplatin compared to the parental cell line. Igrov-1/25 ET exposed to Doxorubicin retained this drug much less, mainly because of a more efficient drug efflux. The cyclosporine analogue SDZ PSC-833 reversed the resistance of Igrov-1/25 ET to ET-743, without any enhancement of the drug activity against the parental Igrov-1 cell line. Igrov-1/25 ET exhibits typical features of cell lines overexpressing the mdr-1 gene and can be a potentially useful tool in selecting ET-743 non-cross-resistant analogues as well as to investigate methods to counteract resistance to this drug. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bénard J, Da Silva J, De Blois M, Boyer P, Duvillard P, Chiric E and Riou G (1985) Characterization of human ovarian adenocarcinoma line, IGROV 1, in tissue culture and in nude mice. Cancer Res 45: 4970–4979
Binaschi M, Supino R, Gambetta RA, Giaccone G, Prosperi E, Capranico G and Zunino F (1995) MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer 62: 84–89
Boesch D, Muller K, Pourtier-Manzanedo A and Loor F (1991) Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a non-immunosuppressive cyclosporin derivative. Exp Cell Res 196: 26–32
Bonfanti M, La Valle E, Fernandez Sousa Faro J-M, Faircloth G, Caretti G, Mantovani R and D'Incalci M (1999) Effect of ecteinascidin-743 (ET-743) on the interaction between DNA bindings proteins and DNA. Anti-cancer Drug Des 14: 179–186
Broggini M, Grandi M, Ubezio P, Geroni C, Giuliani FC and D'Incalci M (1988) Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochem Pharmacol 37: 4423–4431
Cvitkovic E, Riofrio M, Goldwasser F, Delaloge S, Taamma A, Bijnen J, Jimeno JM, Mekranter B, Guzman C, Brain E and Misset JL (1999) Final results of phase 1 study of ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts). Proc ASCO 18: 180a
Erba E, Balconi G, Faretta M, Bergamaschi D, Guidi G, Jimeno J, Faircloth and D'Incalci M (1996) Cell cycle phases perturbations induced by new natural marine compounds. Ann Oncol 7: 82
Ferrero M, Spyratos F, Le Doussal V, Desplaces A and Rouesse J (1990) Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. Cytometry 11: 716–724
Ghielmini M, Colli E, Erba E, Bergamaschi D, Pampallona S, Jimeno J, Faircloth G and Sessa C (1998) In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann Oncol 9: 989–993
Guan Y, Sakai R, Rinehart KL and Wang AHJ (1993) Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 10: 793–818
Jimeno JM, Faircloth G, Cameron L, Meely K, Vega E, Gomez A, FernandezSousa-Faro JM and Rinehart K (1996) Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743). Drugs Fut 21: 1155–1165
Jin S, Lin Y, Magro PG and Scotto KW (1999) Repression of MDR1 gene transcription by ecteinascidin 743. Proc Am Ass Cancer Res 40: 314
Krishan A, Sauerteig A, Andritsch I and Wellham L (1997) Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia 11: 1138–1146
Limonta M, Ubezio P, Catapano CV, Conter V, Costato C, Specchia G, Liso V, Barbui T, Giudici G and D'Incalci M (1991) Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients. Leukemia Res 15: 19–24
Moore IIBM, Seaman FC and Hurley LH (1997) NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 119: 5475–5476
Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A and Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35: 13303–13309
Rayan DP, Supko JG, Eder JP, Lu H, Chabner B, Roper K, Baccala P, Bonefant J, Faircloth G, Guzman C, Jimeno J and Clark JW (1999) A phase I and pharmacokinetic trial of ecteinacidin-743 (ET-743) administered as a 72 hour continuous infusion. Proc ASCO 18: 188a
Rinehart KL, Holt TG, Fregeau NL, Stroh JG, Keifer PA, Li LH and Martin DG (1990) Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 55: 4512–4515
Sambrook J, Fritsch EF and Maniatis T (1989). Molecular Cloning. Cold Spring Harbor Laboratory Press,Cold Spring Harbor
Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G and Giavazzi R (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4: 1977–1983
Zewail-Foote M and Hurley LH (1999) Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42: 2493–2497
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Erba, E., Bergamaschi, D., Bassano, L. et al. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 82, 1732–1739 (2000). https://doi.org/10.1054/bjoc.2000.1224
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1224
Keywords
This article is cited by
-
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
British Journal of Cancer (2019)
-
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
British Journal of Cancer (2015)
-
Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
Molecular Cancer (2010)
-
Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
Cancer Chemotherapy and Pharmacology (2009)
-
Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
Investigational New Drugs (2007)